120173-57-1
Chemical Structure
Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH
Synonym(s): Fmoc-Ser-(GalNAc(Ac)3-alpha-D)-OH; Fmoc-Ser[GalNAc(Ac)3-α-D]-OH; Fmoc-Ser(Ac3AcNH-α-Gal)-OH
- CAS No.: 120173-57-1
- Formula:C32H36N2O13
- Molecular Weight:656.63
IUPAC Name: N-(((9H-fluoren-9-yl)methoxy)carbonyl)-O-((2S,3R,4R,5R,6R)-3-acetamido-4,5-diacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)-L-serine
InChIKey: ORICVOOXZDVFIP-VOZJJELXSA-N
SMILES: O=C(N[C@H](C(O)=O)CO[C@@H](O[C@H](COC(C)=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O)[C@@H]1NC(C)=O)OCC2C3=CC=CC=C3C4=CC=CC=C24
Biological Activity: Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH (Fmoc-Ser-(GalNAc(Ac)3-alpha-D)-OH) is a protected glycosylated amino acid and Tn antigen. Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH serves as a building block in the solid-phase synthesis of Tn-based cancer vaccine constructs. Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH supports solid-phase peptide synthesis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH | 99.12% | Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH (Fmoc-Ser-(GalNAc(Ac)3-alpha-D)-OH) is a protected glycosylated amino acid and Tn antigen. Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH serves as a building block in the solid-phase synthesis of Tn-based cancer vaccine constructs. Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH supports solid-phase peptide synthesis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH (Standard) | ≥98% | Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH (Standard) is the analytical standard of Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH (HY-104004). This product is intended for research and analytical applications. Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH (Fmoc-Ser-(GalNAc(Ac)3-alpha-D)-OH) is a protected glycosylated amino acid and Tn antigen. Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH serves as a building block in the solid-phase synthesis of Tn-based cancer vaccine constructs. Fmoc-Ser (O-α-D-GalNAc (OAc) 3)-OH supports solid-phase peptide synthesis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Abdel-Aal AB, et al. Design of fully synthetic, self-adjuvanting vaccine incorporating the tumor-associated carbohydrate Tn antigen and lipoamino acid-based Toll-like receptor 2 ligand. J Med Chem. 2012;55(15):6968-6974. [Content Brief]
- [2]. Arsequell G, et al. Synthesis, biological evaluation and structural characterization of novel glycopeptide analogues of nociceptin N/OFQ. Org Biomol Chem. 2011;9(17):6133-6142. [Content Brief]
